Skip to main content
Fig. 1 | Critical Care

Fig. 1

From: Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction

Fig. 1

S100A8/A9 is elevated in critically ill sepsis patients with left ventricular dysfunction. S100A8/A9 was measured in plasma collected upon admittance into the ICU. A Comparison of plasma S100A8/A9 levels in patients with severe sepsis, with or without left ventricular dysfunction (LV Dys). B ROC analysis of the ability of S100A8/A9 at admission to identify LV Dys. C Relationship between S100A8/A9 levels and the site of infection. D Correlation between plasma S100A8/A9 and SOFA disease severity score. Comparison of S100A8/A9 in patients with or without LV Dys was performed using the Mann–Whitney U test. Spearman correlation analysis was used to assess the relationship between S100A8/A9 and the SOFA score

Back to article page

Critical Care

ISSN: 1364-8535